ArticleFrontiers in oncology2025
High-grade non-muscle invasive urothelial carcinoma in dogs and humans share specific expression of integrin α5β1.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Urothelial carcinoma (UC) accounts for more than 90% of all bladder cancers both in humans and dogs. Human and canine UC share many genetic mutations and tumor markers and clinical and therapeutic interventions. The unmet clinical needs are similar such as the early detection and treatment of the high-grade residual disease responsible for tumor recurrence and progression. The aim of this study was to investigate the expression of the α5β1 integrin and its specificity in high-grade UC in humans and dogs, a marker recently reported in the human bladder Methods: Expression of integrin α5β1 was established by immunohistochemistry in 67 human bladder samples [four non-tumor tissues, 10 low-grade, 10 intermediate-grade, and 43 high-grade non-muscle invasive bladder cancer (NMIBC)] and 12 canine bladder tumor specimens. Results: The α5β1 integrin was not expressed by urothelial cells in the conditions of inflammatory cystitis, actinic cystitis, benign hyperplasia, and low/intermediate grade NMIBC; it was identified as a specific marker expressed only by the malignant cells in the urothelium in 81% of human and all canine high-grade NMIBC. Conclusions: The expression of α5β1 integrin is a specific marker of high-grade UC located in the urothelium of humans and dogs and might be tested for targeted delivery of contrast agents or drugs. Given the close similarity between high-grade UC in humans and dogs, basic research in the two species and comparative data analysis could strengthen the prospects for rapid development of an improved clinical strategy for the identification and treatment of the small neoplastic lesions responsible for residual high-grade in both species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.